Single Fluid-Filled Intragastric Balloon Safe and Effective for Inducing Weight Loss in a Real-World Population
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background & Aims: The Orbera intragastric balloon (OIB) is a single fluid‐filled intragastric balloon approved for the induction of weight loss and treatment of obesity. However, little is known about the effectiveness and safety of the OIB outside clinical trials, and since approval, the Food and Drug Administration has issued warnings to health care providers about risk of balloon hyperinflation requiring early removal, pancreatitis, and death. We analyzed data on patients who have received the OIB since its approval to determine its safety, effectiveness, and tolerance in real‐world clinical settings. Methods: We performed a postregulatory approval study of the safety and efficacy of the OIB, and factors associated with intolerance and response. We collected data from the Mayo Clinic's database of patient demographics, outcomes of OIB placement (weight loss, weight‐related comorbidities), technical aspects of insertion and removal, and adverse events associated with the device and/or procedure, from 8 centers (3 academic, 5 private, 4 surgeons, and 4 gastroenterologists). Our final analysis comprised 321 patients (mean age, 48.1 ± 11.9 y; 80% female; baseline body mass index, 37.6 ± 6.9). Exploratory multivariable linear and logistic regression analyses were performed to identify predictors of success and early balloon removal. Primary effectiveness outcomes were percentage of total body weight lost at 3, 6, and 9 months. Primary and secondary safety outcomes were rates of early balloon removal, periprocedural complications, dehydration episodes requiring intravenous infusion, balloon migration, balloon deflation or hyperinflation, pancreatitis, or other complications. Results: Four patients had contraindications for placement at the time of endoscopy. The balloon was safely removed in all instances with an early removal rate (before 6 months) in 16.7% of patients, at a median of 8 weeks after placement (range, 1–6 mo). Use of selective serotonin or serotonin‐norepinephrine re‐uptake inhibitors at the time of balloon placement was associated with increased odds of removal before 6 months (odds ratio, 3.92; 95% CI, 1.24–12.41). Total body weight lost at 3 months was 8.5% ± 4.9% (n = 204), at 6 months was 11.8% ± 7.5% (n = 199), and at 9 months was 13.3% ± 10% (n = 47). At 6 months, total body weight losses of 5%, 10%, and 15% were achieved by 88%, 62%, and 31% of patients, respectively. Number of follow‐up visits and weight loss at 3 months were associated with increased weight loss at 6 months (&bgr; = 0.5 and 1.2, respectively) (P < .05). Mean levels of cholesterol, triglycerides, low‐density lipoprotein, and hemoglobin A1c, as well as systolic and diastolic blood pressure, were significantly improved at 6 months after OIB placement (P < .05). Conclusions: In an analysis of a database of patients who received endoscopic placement of the OIB, we found it to be safe, effective at inducing weight loss, and to reduce obesity‐related comorbidities in a real‐world clinical population. Rates of early removal (before 8 weeks) did not differ significantly between clinical trials and the real‐world population, but were affected by use of medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918 · cited 1×
“Both the global burden of obesity study and a recent large individual-participant data meta-analyses of 239 prospective studies limited to never-smokers with no pre-existing disease showed that patients with mild-tomoderate obesity (BMI, 30–40 kg/m(2)) are the highest contributors to the burden of disease in terms of…”
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934 · cited 1×
“Bariatric surgery continues to be the most effective option for durable weight loss, but it carries its own set of risks and costs.(6,7) Therefore, endoscopic bariatric therapies were developed to help bridge the gap between effectiveness and procedural risk to offer patients with obesity significant weight loss that…”
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Brethauer, S. A., Navaneethan, S. D., Aminian, A., Pothier, C. E., Kim, E. S. H., Nissen, S. E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401329 · Cited by 1,901 · cited 1×
“Bariatric surgery continues to be the most effective option for durable weight loss, but it carries its own set of risks and costs.(6,7) Therefore, endoscopic bariatric therapies were developed to help bridge the gap between effectiveness and procedural risk to offer patients with obesity significant weight loss that…”
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 1×
“In response to significant caloric restriction and loss of body fat stores, there are physiologic counter-regulatory processes that increase hunger, decrease satiety, and increase metabolic efficiency.(23) We previously have shown that the OIB modulates this compensatory hunger in response to caloric restriction by de…”
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Self-citationGastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Trends in mortality in bariatric surgery: a systematic review and meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., & Sledge, I. (2007) · Surgery · doi:10.1016/j.surg.2007.07.018 · Cited by 685
Four-year weight losses in the Look AHEAD study: factors associated with long-term success
Wadden, T. A., Neiberg, R. H., Wing, R. R., Clark, J. M., Delahanty, L. M., Hill, J. O., Krakoff, J., Otto, A., Ryan, D. H., Vitolins, M. Z., et al. (2011) · Obesity · doi:10.1038/oby.2011.230 · Cited by 465
Szarka, L. A., Camilleri, M., Vella, A., Burton, D., Baxter, K., Simonson, J., & Zinsmeister, A. R. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.01.009 · Cited by 209
Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial.
Courcoulas, A., Abu Dayyeh, B. K., Eaton, L., Robinson, J., Woodman, G., Fusco, M., Shayani, V, Billy, H., Pambianco, D., & Gostout, C. (2017) · International Journal of Obesity · doi:10.1038/ijo.2016.229 · Cited by 167 · cited 2×
“Recent US multicenter randomized clinical trials showed the superiority of the OIB plus lifestyle interventions over lifestyle interventions alone, with patients losing 3 times more weight 6 months into balloon therapy.(11) However, the effectiveness and safety of the OIB outside clinical trials in the United States i…”
Self-citationThomas, C. E., Mauer, E. A., Shukla, A. P., Rathi, S., & Aronne, L. J. (2016) · Obesity · doi:10.1002/oby.21533 · Cited by 124
Self-citationPopov, V. B., Ou, A., Schulman, A. R., & Thompson, C. C. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.530 · Cited by 100
Cited by
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.10.025 · Cited by 608
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0406 · Cited by 510
Mechanick, J. I., Apovian, C., Brethauer, S., Timothy Garvey, W., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah‐Pollack, R., Seger, J., et al. (2020) · Obesity · doi:10.1002/oby.22719 · Cited by 389
Risi, R., Rossini, G., Tozzi, R., Pieralice, S., Monte, L., Masi, D., Castagneto-Gissey, L., Gallo, I. F., Strigari, L., Casella, G., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.03.022 · Cited by 68
Precision medicine in adult and pediatric obesity: a clinical perspective
Bomberg, E. M., Ryder, J. R., Brundage, R. C., Straka, R. J., Fox, C. K., Gross, A. C., Oberle, M. M., Bramante, C. T., Sibley, S. D., & Kelly, A. S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819863022 · Cited by 52
Metadata
- Authors
- Vargas, E. J., Pesta, C. M., Bali, A., Ibegbu, E., Bazerbachi, F., Moore, R. L., Kumbhari, V., Sharaiha, R. Z., Curry, T. W., DosSantos, G., Schmitz, R., Agnihotri, A., Novikov, A. A., Pitt, T., Dunlap, M. K., Herr, A., Aronne, L., Ledonne, E., Kadouh, H. C., Cheskin, L. J., Mundi, M. S., Acosta, A., Gostout, C. J., & Abu Dayyeh, B. K.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 16
- Issue
- 7
- Pages
- 1073-1080.e1
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2786408414
- Cited by
- 75
- References
- 17
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.